^
    Back
    Association details:
    Biomarker:PD-L1 negative
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1-negative tumour...Options...Pembrolizumab plus platinum/5-FU…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1-negative tumour...Options...Pembrolizumab plus platinum/5-FU…
    Secondary therapy:
    Chemotherapy; 5-fluorouracil